The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure
NCT ID: NCT00981071
Last Updated: 2010-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2009-05-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Co-Infection of NTM in Patients With Smear Positive Pulmonary TB
NCT00567151
Latent Tuberculosis Infection in Korean Health Care Workers
NCT03010111
Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients
NCT00962676
QuantiFERON Change During Anti-tuberculosis Medication
NCT01038830
Prevalence of Latent Tuberculosis (TB) Infection Diagnosed by Interferon-gamma Release Assay and Tuberculin Skin Tests in Patients With Old Healed TB
NCT01099098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A platoon with TB outbreak
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Armed Forces Capital Hospital, Republic of Korea
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Armed Forces Capital Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jae-Joon Yim, MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QFTconversion
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.